论文部分内容阅读
目的探讨维生素D3添加治疗缓解复发型多发性硬化(RRMS)患者的临床疗效和安全性。方法将50例缓解复发型多发性硬化(RRMS)患者随机分成维生素D3组和激素组,每组各25例,维生素D3组在激素治疗的基础上添加骨化三醇胶丸口服,治疗前后检测外周血T细胞亚群CD4+、CD8+、CD4+/CD8+、Th1、Th2数量,评定NIHSS分值,观察并记录治疗期间药物的安全性及副作用。结果治疗前维生素D3组与激素组在年龄、病程、性别以及NIHSS评分比较差异无统计学意义(P>0.05),治疗后CD8+、CD4+/CD8+、Th2数与治疗前比较及治疗后2组间比较差异均无统计学意义(P>0.05),治疗后CD4+、Th1数、NIHSS评分与治疗前比较及治疗后2组间比较差异有统计学意义(P<0.05)。结论维生素D3添加治疗缓解复发型多发性硬化(RRMS)患者具有较好的临床疗效。
Objective To investigate the clinical efficacy and safety of vitamin D3 in relieving relapsed multiple sclerosis (RRMS). Methods Fifty patients with recurrent multiple sclerosis (RRMS) were randomly divided into vitamin D3 group and hormone group, 25 in each group. Vitamin D3 group was given orally with calcitriol capsules on the basis of hormone therapy. Before and after treatment, The number of CD4 +, CD8 +, CD4 + / CD8 +, Th1 and Th2 in peripheral blood T lymphocyte subsets was assessed. NIHSS scores were assessed. The safety and side effects of the drugs during the treatment were observed and recorded. Results There was no significant difference in age, course of disease, gender and NIHSS scores between the vitamin D3 group and the hormone group before treatment (P> 0.05). After treatment, the levels of CD8 +, CD4 + / CD8 + There was no significant difference between the two groups (P> 0.05). After treatment, the CD4 +, Th1, NIHSS scores were significantly different from those before treatment and after treatment (P <0.05). Conclusion Vitamin D3 supplementation has a good clinical effect in relieving relapsed multiple sclerosis (RRMS).